Brilaroxazine hydrochloride is under clinical development by Reviva Pharmaceuticals and currently in Phase I for Major Depressive Disorder.

Long-Acting Injectable Program is under clinical development by Intra-Cellular Therapies and currently in Phase I for Schizoaffective Disorder.

Here’s a look at the best and worst states in each of our four data categories: mental health provider ratio, percentage of ...

INR:7343. chunk base seed map Biogen to develop breakthrough depression and movement disorder treatments with $3.1 billion in R&D collaboration The era of cen ...

Nexstim’s Annual Report 2024 will be published and available on the Company’s website on Thursday, March 6, 2025. The Annual General Meeting is tentatively scheduled to be held on Thursday, March 27, ...

The legalization of “magic” mushrooms comes as people increasingly turn to psychedelics to treat anxiety, depression and other disorders ...

There were approximately 10,000 patients in the U.S. on treatment at the end of September ... and there is now the sole focus ...

One in every five individuals worldwide experiences symptoms of mental health illness, according to the World Health ...

The sale of antidepressants and mood elevators in India surged from Rs 1,540 crore in 2020 to Rs 2,536 crore by Nov 2024.

ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)ACCORD-2 Phase 3 ...

The "Wonder Woman" star recalls her daughter, Ori, was born during a "moment of uncertainty and fear" The post Gal Gadot ...